[go: up one dir, main page]

ATE185489T1 - Polymere als kontrastmittel bei magnetischer resonanz - Google Patents

Polymere als kontrastmittel bei magnetischer resonanz

Info

Publication number
ATE185489T1
ATE185489T1 AT95111117T AT95111117T ATE185489T1 AT E185489 T1 ATE185489 T1 AT E185489T1 AT 95111117 T AT95111117 T AT 95111117T AT 95111117 T AT95111117 T AT 95111117T AT E185489 T1 ATE185489 T1 AT E185489T1
Authority
AT
Austria
Prior art keywords
magnetic resonance
polymers
contrast agents
polymer
biocompatible
Prior art date
Application number
AT95111117T
Other languages
English (en)
Inventor
Evan C Unger
Original Assignee
Imarx Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imarx Pharmaceutical Corp filed Critical Imarx Pharmaceutical Corp
Application granted granted Critical
Publication of ATE185489T1 publication Critical patent/ATE185489T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1803—Semi-solid preparations, e.g. ointments, gels, hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Molecular Biology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Signal Processing (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Graft Or Block Polymers (AREA)
AT95111117T 1990-04-10 1991-04-09 Polymere als kontrastmittel bei magnetischer resonanz ATE185489T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50712590A 1990-04-10 1990-04-10

Publications (1)

Publication Number Publication Date
ATE185489T1 true ATE185489T1 (de) 1999-10-15

Family

ID=24017359

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95111117T ATE185489T1 (de) 1990-04-10 1991-04-09 Polymere als kontrastmittel bei magnetischer resonanz
AT91908011T ATE153860T1 (de) 1990-04-10 1991-04-09 Polymere und ihre verwendung als kontrastmittel bei der bilderzeugung mit magnetischer resonanz

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT91908011T ATE153860T1 (de) 1990-04-10 1991-04-09 Polymere und ihre verwendung als kontrastmittel bei der bilderzeugung mit magnetischer resonanz

Country Status (8)

Country Link
EP (2) EP0693288B1 (de)
JP (1) JPH05506227A (de)
AT (2) ATE185489T1 (de)
DE (2) DE69131721T2 (de)
DK (1) DK0526503T3 (de)
ES (2) ES2103809T3 (de)
GR (1) GR3023806T3 (de)
WO (1) WO1991015753A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
US5948387A (en) * 1990-06-01 1999-09-07 Imarx Pharmaceutical Corp. Contrast media for ultrasonic imaging
AU650466B2 (en) * 1990-06-01 1994-06-23 Evan C. Unger Contrast media for ultrasonic imaging
US5420176A (en) * 1990-06-01 1995-05-30 Imarx Pharmaceutical Corp. Contrast media for ultrasonic imaging
DE4117782C2 (de) * 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel
EP0614527A4 (de) * 1991-11-19 1998-06-03 Evan C Unger Kontrastmittel auf der basis von gelförmigen teilchen für eine verbesserte bilderzeugung.
US5323780A (en) * 1992-08-07 1994-06-28 University Of Florida Research Foundation, Inc. Artifact-free imaging contrast agent
US5514379A (en) * 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
EP0665729B1 (de) * 1992-09-04 2003-05-07 The General Hospital Corporation Diagnostische und therapeutische Einheiten enthaltende biokompatible Polymere
US5756688A (en) * 1992-10-14 1998-05-26 Sterling Winthrop Inc. MR imaging compositions and methods
EP0664713B1 (de) * 1992-10-14 2000-01-19 Nycomed Imaging As Therapeutische und diagnostische bilderzeugungzusammensetzung und verfahren zur herstellung
EP0664819B1 (de) * 1992-10-14 1997-08-06 Nycomed Imaging As Chelatpolymere
US5817292A (en) * 1992-10-14 1998-10-06 Nycomed Imaging As MR imaging compositions and methods
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
ATE187079T1 (de) 1994-09-27 1999-12-15 Nycomed Imaging As Kontrastmittel
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
WO1999052564A1 (en) * 1998-04-09 1999-10-21 Nycomed Imaging A.S Method
DE19942278C2 (de) * 1999-09-04 2001-09-13 Messer Griesheim Gmbh Quantitative Bestimmung des Xenongehaltes in Flüssigkeiten mit Hilfe der NMR-Spektroskopie
WO2007067417A1 (en) 2005-12-05 2007-06-14 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
BRPI0712066A2 (pt) * 2006-05-17 2011-12-20 Otsuka Pharma Co Ltd meio de contraste para ressonáncia magnética usando polietilenoglicol e método para captação de imagens de ressonáncia magnética
CN101678123B (zh) 2007-05-09 2014-07-16 日东电工株式会社 包含疏水性化合物和聚氨基酸结合物的组合物
KR101303567B1 (ko) * 2011-03-08 2013-09-23 주식회사 인트론바이오테크놀로지 카르복실기가 도입된 만난으로 코팅된 자기공명영상 조영제 및 그것의 제조 방법
IL296875A (en) 2014-12-31 2022-12-01 Lantheus Medical Imaging Inc Lipid-encapsulated gas microsphere compositions and related methods
US20170319718A1 (en) 2016-05-04 2017-11-09 Lantheus Medical Imaging, Inc. Methods and devices for preparation of ultrasound contrast agents
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069306A (en) * 1974-03-14 1978-01-17 Pharmacia Aktiebolag X-ray contrast preparation containing a hydrophilic polymer containing amino groups
US4775522A (en) * 1983-03-04 1988-10-04 Children's Hospital Research Foundation, A Division Of Children's Hospital Medical Center NMR compositions for indirectly detecting a dissolved gas in an animal
US4586511A (en) * 1983-03-04 1986-05-06 Children's Hospital Medical Center Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance
DE3316703A1 (de) * 1983-05-04 1984-11-08 Schering AG, 1000 Berlin und 4709 Bergkamen Orales kontrastmittel fuer die kernspintomographie und dessen herstellung
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
DE3577185D1 (de) * 1984-11-01 1990-05-23 Nycomed As Paramagnetische kontrastmittel fuer die anwendung in "in vivo" nmr-diagnostischen methoden und die herstellung davon.
US4849210A (en) * 1985-05-08 1989-07-18 Molecular Biosystems, Inc. Magnetic resonance imaging of liver and spleen with superparamagnetic contrast agents
JPS62153229A (ja) * 1985-12-27 1987-07-08 Nippon Oil Co Ltd 皮膚マ−カ−
US4871716A (en) * 1986-02-04 1989-10-03 University Of Florida Magnetically responsive, hydrophilic microspheres for incorporation of therapeutic substances and methods of preparation thereof
US4729892A (en) * 1986-03-21 1988-03-08 Ciba-Geigy Corporation Use of cross-linked hydrogel materials as image contrast agents in proton nuclear magnetic resonance tomography and tissue phantom kits containing such materials
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US4933441A (en) * 1987-01-27 1990-06-12 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
US4838274A (en) * 1987-09-18 1989-06-13 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance imaging
GB8813425D0 (en) * 1988-06-07 1988-07-13 Hall L D Magnetic resonance imaging
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US4996041A (en) * 1988-08-19 1991-02-26 Toshiyuki Arai Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system
GB8916780D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions

Also Published As

Publication number Publication date
DE69126429D1 (de) 1997-07-10
JPH05506227A (ja) 1993-09-16
DE69126429T2 (de) 1997-10-23
EP0526503A1 (de) 1993-02-10
ATE153860T1 (de) 1997-06-15
GR3023806T3 (en) 1997-09-30
EP0526503B1 (de) 1997-06-04
ES2138122T3 (es) 2000-01-01
DE69131721D1 (de) 1999-11-18
WO1991015753A1 (en) 1991-10-17
DE69131721T2 (de) 2000-03-02
DK0526503T3 (da) 1997-10-27
EP0526503A4 (en) 1993-02-24
EP0693288B1 (de) 1999-10-13
ES2103809T3 (es) 1997-10-01
EP0693288A1 (de) 1996-01-24

Similar Documents

Publication Publication Date Title
ATE185489T1 (de) Polymere als kontrastmittel bei magnetischer resonanz
GR3025658T3 (en) Contrast media for ultrasonic imaging
ATE201217T1 (de) Gasgefüllte mikrospheren enthaltende kontrastmittel zur diagnostischen bilderzeugung
ATE264698T1 (de) Medizinisches material und verfahren zu seiner herstellung
DE69006472D1 (en) Zahnärztliche Zusammensetzungen, Verfahren zur Herstellung von geformten, zahnärztlichen Artikeln via "photoiniferte Polymerisation" von zahnärztlichen Zusammensetzungen und dadurch erzeugte geformte, zahnärztliche Artikel.
NO911604L (no) Suspensjon av vannopploeselig polymer og fremgangsmaate tildens fremstilling.
FI955525A7 (fi) Pintamodifioituja, biologisesti yhteensopivia kalvoja
DE69033460D1 (de) Vernetzter polymerelektrolyt und verfahren zu seiner herstellung
DE68904132D1 (de) Verfahren zur herstellung von festen elastischen polymerpartikeln mit offenen poren.
DE69429484D1 (de) Behälter für Blut
DE68923319D1 (de) Fluorkohlenstoff- Membranen und Verfahren zur Herstellung von Fluorkohlenstoff-Membranen.
DE58904699D1 (de) 1-olefin isoblockpolymer und verfahren zu seiner herstellung.
ATE77755T1 (de) Kontrastmittel mit stabilen, freien radikalen.
DE69101914D1 (de) Verzweigte fructo-oligosacchariden, verfahren zu ihrer herstellung und verwendung von diese enthaltenden mitteln.
KR970702733A (ko) 활성물질의 방출 조절용 콜라겐 제제(collagen preparation the controlled release of active substances)
DE69013922D1 (de) Magnetkopf-aufhängevorrichtung zur verwendung bei fotografischen filmen.
PT795605E (pt) Receptor de lipoproteina de baixa densidade desnaturada
DE68928610D1 (de) Passiver Ausgleichskörper zur Korrektur von (3,2)- und (3,-2)-harmonischen Gliedern bei magnetischen Resonanzmagneten
DE69023429D1 (de) Poröser Sinterkörper und Verfahren zu seiner Herstellung.
TW222000B (de)
DE69321056D1 (de) Monomerer Diester, sein Polymer, wasserenthaltende weiche Kontaktlinse und Lösung zur Herstellung von Kontaktlinsen
DE69105026D1 (de) Chirurgischer Nähfaden und Verfahren zu seiner Herstellung.
IT9067588A0 (it) Apparecchiatura atta ad accertare e misurare le condizioni di efficienza fisica di utenti di autoveicoli e le capacita' di guida degli stessi con e senza l'ausilio di adattamenti e/o protesi.
DE59107953D1 (de) Verwendung von wässrigen Polymerisatdispersionen
DE68910676D1 (de) Verwendung von Creosot als antispastischer Wirkstoff.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties